Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600 Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT03416933
What this trial is testing

Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma

Who this might be right for
Melanoma (Skin)
Institut de Cancérologie de Lorraine 35
Not applicableStudy completedNCT03663647
What this trial is testing

Advanced Melanoma in Russian Experience

Who this might be right for
Cutaneous Melanoma, Stage IVBRAF V600 Mutation
MelanomaPRO, Russia 382
Testing effectiveness (Phase 2)Study completedNCT03220035
What this trial is testing

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+20 more
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT03235245
What this trial is testing

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Who this might be right for
Unresectable Stage III MelanomaStage IV Melanoma
European Organisation for Research and Treatment of Cancer - EORTC 271
Early research (Phase 1)Study completedNCT02082665
What this trial is testing

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

Who this might be right for
Cancer
GlaxoSmithKline 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT04324112
What this trial is testing

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Who this might be right for
Hairy Cell Leukemia
National Cancer Institute (NCI) 28
Early research (Phase 1)Looking for participantsNCT07561554
What this trial is testing

Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

Who this might be right for
Solid Tumors (Phase 1)
Haisco Pharmaceutical Group Co., Ltd. 159
Post-approval studies (Phase 4)Study completedNCT01739764
What this trial is testing

An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

Who this might be right for
Neoplasms
Hoffmann-La Roche 215
Testing effectiveness (Phase 2)Study completedNCT02296112
What this trial is testing

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Who this might be right for
Recurrent MelanomaStage IIIB MelanomaStage IIIC Melanoma+1 more
Vanderbilt-Ingram Cancer Center 9
Not applicableStudy completedNCT04911998
What this trial is testing

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Who this might be right for
Melanoma (Skin)Metastatic MelanomaBRAF V600 Mutation
Pierre Fabre Medicament 400
Testing effectiveness (Phase 2)Ended earlyNCT04488003
What this trial is testing

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Who this might be right for
Advanced Solid TumorBRAF Gene MutationBRAF Gene Alteration+6 more
BioMed Valley Discoveries, Inc 104
Testing effectiveness (Phase 2)Study completedNCT02836548
What this trial is testing

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

Who this might be right for
MelanomaSkin Neoplasms
The Netherlands Cancer Institute 33
Early research (Phase 1)Temporarily pausedNCT04418167
What this trial is testing

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Who this might be right for
Solid Tumors
JS InnoPharm, LLC 71
Testing effectiveness (Phase 2)Study completedNCT02768207
What this trial is testing

Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Who this might be right for
Metastatic Melanoma
Hoffmann-La Roche 40
Testing effectiveness (Phase 2)WithdrawnNCT03794297
What this trial is testing

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

Who this might be right for
Erdheim-Chester Disease
National Cancer Institute (NCI)
Early research (Phase 1)UnknownNCT03781219
What this trial is testing

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

Who this might be right for
Solid Tumor
Shanghai Kechow Pharma, Inc. 45
Not applicableStudy completedNCT05806268
What this trial is testing

Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

Who this might be right for
BRAF v600 Mutated Metastatic Melanoma
Novartis Pharmaceuticals 214
Early research (Phase 1)Study completedNCT04462471
What this trial is testing

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Who this might be right for
Thyroid CarcinomaThyroid CancerThyroid Cancer, Follicular+3 more
Memorial Sloan Kettering Cancer Center 8
Early research (Phase 1)Study completedNCT01436656
What this trial is testing

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Who this might be right for
Melanoma and Metastatic Colorectal Cancer
Pfizer 107
Testing effectiveness (Phase 2)UnknownNCT05528406
What this trial is testing

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation

Who this might be right for
Solid Tumor
Shanghai Henlius Biotech 30
Next Page